Preliminary findings presented at AMP 2026 suggest the technology can detect structural variants in hematologic malignancies directly from peripheral blood without the need for cell culture.
Researchers from Augusta University and The University of Texas MD Anderson Cancer Center are presenting research on electronic genome mapping for structural variant detection in hematologic malignancies at the Association for Molecular Pathology annual meeting, Nov 10-14 in Seattle, Nabsys 2.0 announced.
Characterizing hematologic malignancies often requires multiple technologies, including karyotyping, fluorescence in situ hybridization, chromosomal microarray, and sequencing. According to the company, electronic genome mapping offers a complementary, high-resolution, genome-wide approach to analyzing structural and copy number variants in one assay using the Nabsys OhmX Platform.
Session Details
Ravindra Kolhe, MD, PhD, professor and chair of pathology at Augusta University, and Rashmi Kanagal-Shamanna, MD, professor of hematopathology and molecular diagnostics at MD Anderson, will present at the Innovation Spotlight Session (stage 1) on Friday, Nov 13. Their talk is titled “Electronic Genome Mapping for Structural Variant Detection: Implications for Advancing Clinical Research in Heme Malignancies.”
“Structural variants are central to disease classification and risk assessment across many hematologic malignancies, yet labs still rely on a combination of karyotyping, FISH, and other molecular methods to identify them,” says Kolhe in a release. “In our initial study, electronic genome mapping detected every abnormality identified by standard cytogenetic testing and provided additional molecular insights in complex cases. I look forward to sharing these findings with the AMP community and discussing how [electronic genome mapping] could help streamline cytogenomic analysis in clinical research.”
Kanagal-Shamanna points to limitations of conventional cytogenetics. “Conventional cytogenetics depends on dividing bone marrow aspirates through invasive procedures and can be often hemodilute, and sometimes of insufficient volume to perform assays,” she says in a release. “Our preliminary data suggests that with [electronic genome mapping], we can detect translocations, deletions and complex rearrangements directly from peripheral blood, with no culture needed and at a resolution far beyond karyotyping.”
Barrett Bready, MD, founder and CEO of Nabsys, says in a release that collaboration with the hematopathology community is essential to the technology’s progress. “Their work is critical to building the evidence, confidence, and clinical research understanding needed for broader adoption of [electronic genome mapping],” he says.
At the conference, Nabsys will showcase the OhmX Platform and demonstrate Nabsys Navigator, its cloud-based platform for electronic genome mapping analysis and visualization. Available pipelines include SV-Discover for genome-wide structural variant analysis and SV-Verify for confirmation of structural variants identified by other technologies.
Attendees can also preview the forthcoming hematologic malignancy analysis software and provide feedback on data presentation, navigation, access to information, and overall interface design.
The OhmX Platform is for Research Use Only and is not for use in diagnostic procedures.
